ANI PHARMACEUTICALS INC
Close on Oct 19, 2026
- Market cap
- $1.59B
- P/E (TTM)
- 15.4
- Dividend yield
- –
About Ani Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
ANI Pharmaceuticals is a biopharmaceutical company that develops, produces, and commercializes therapeutic medications. Its operations comprise rare disease, generic, and branded pharmaceutical segments. The company's portfolio features key therapies such as Cortrophin Gel for chronic autoimmune conditions, ophthalmic treatments ILUVIEN and YUTIQ, and over 120 generic drugs spanning diverse indications, alongside established branded pharmaceuticals. Its products serve patients with specialized or rare disorders, individuals requiring generic medicines, and healthcare professionals across multiple medical specialties.
ANI Pharmaceuticals operates three manufacturing facilities in the United States, with two locations in Baudette, Minnesota, and one in East Windsor, New Jersey. Internationally, the company maintains direct marketing operations in Germany, the United Kingdom, Portugal, and Ireland, complemented by commercial partnerships across Europe, Asia, and the Middle East. It also distributes products through a specialty pharmacy network and collaborates with contract manufacturing partners. The provided text does not state the company's headquarters.
Summary of the business section of Ani Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ANI PHARMACEUTICALS INC
- Headquarters
- Princeton, NJ
- Address
- 104 Carnegie Center Drive Suite 300 08540
- Phone
- (609) 759-1810
- Website
- anipharmaceuticals.com
- Employees
- 970, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- EisnerAmper LLP, Iselin, New Jersey
Stock & identifiers
- Ticker
- ANIP
- Exchange
- Nasdaq
- Shares outstanding
- 23M, Jul 31, 2026
- Public float
- $1.30B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 1-for-6 reverse, Jul 18, 2013; 1-for-6 reverse, Aug 1, 2012; 1-for-6 reverse, Jun 4, 2012; 1-for-10 reverse, Jun 3, 2002
- SEC CIK
- 1023024
- CUSIP
- 00182C103
- ISIN
- US00182C1036
- LEI
- 5493000T6CXTND40YH31
- EIN
- 58-2301143
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Nikhil Lalwani | PRESIDENT & CEO, Director | 339,089 |
| Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS, Director | 537,976 |
| Stephen P. Carey | SVP & CFO | 168,993 |
| Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 73,924 |
| Ori Gutwerg | SVP, GENERICS | 75,534 |
| Thomas Andrew Rowland | SVP, HEAD - ESTABLISHED BRANDS | 38,271 |
| Christopher Mutz | HEAD OF RARE DISEASE | 91,309 |
| Krista Davis | SVP, CHIEF HR OFFICER | 51,946 |
| Chad Gassert | SVP - CORP. DEV. & STRATEGY | 233,406 |
| Jeanne Thoma | Director | 26,762 |
| Henry O. Gosebruch | Director | 6,662 |
| Matthew J. Leonard | Director | 11,221 |
| Thomas Haughey | Director | 38,878 |
| Antonio R. Pera | Director | 27,017 |
| Renee P. Tannenbaum | Director | 29,514 |
| Patrick D. Walsh | Director | 38,432 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Nikhil Lalwani | $10.28M | $21.32M | $2.82M | $272 | $72 |
| FY2024 Nikhil Lalwani | $8.86M | $10.82M | $2.35M | $190 | $62 |
| FY2023 Nikhil Lalwani | $8.08M | $15.10M | $2.08M | $190 | $63 |
| FY2022 Former | $0 | $0 | $1.54M | $139 | $65 |
| FY2022 Interim | $0 | $0 | $1.54M | $139 | $65 |
| FY2022 Nikhil Lalwani | $5.11M | $4.62M | $1.54M | $139 | $65 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of January 2026, we have 970 employees, of which 753 are in the U.S.”
Corporate history
Events identified from SEC filings